The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
 
Michael Bitzer
Consulting or Advisory Role - Bayer/Vital; Bristol-Myers Squibb; Eisai Germany; Incyte; MSD Sharp & Dome GmbH; Roche Pharma AG; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Merck
 
Christopher Hackenbruch
No Relationships to Disclose
 
Jens Bauer
Patents, Royalties, Other Intellectual Property - Listed as inventor on a patent related to DNAJB1-PRKACA T cell epitopes (Application number: EP21214728.4)
 
Jonas S. Heitmann
Travel, Accommodations, Expenses - Synimmune
 
Yacine Maringer
Patents, Royalties, Other Intellectual Property - Listed as inventor on a patent related to the DNAJB1-PRKACA T cell epitopes (Application number: EP21214728.4)
 
Annika Nelde
Patents, Royalties, Other Intellectual Property - I have patents pending on peptide based vaccines
 
Helmut R. Salih
Stock and Other Ownership Interests - Immatics
Consulting or Advisory Role - Novartis; Pfizer; Philogen; Synimmune
Research Funding - ABL Bio
Patents, Royalties, Other Intellectual Property - Inventor on several patents in the field of caner immunotherapy
(OPTIONAL) Uncompensated Relationships - TWYCE GmbH
 
Juliane S. Walz
Research Funding - GlaxoSmithKline; Roche Pharma AG
Patents, Royalties, Other Intellectual Property - CoVac-1 peptide cocktail, Application number: PCT/EP 20 190 070.1;; Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar HCC and other cancers, Application number: EP 2121472; SARS-CoV-2 CD8+ und CD4+ T cell epitopes, Application number: PCT/EP 20 169 047.6